Donald Ogilvie
- Oncology top 2%
- HER2/EGFR in Cancer Research 12
- PARP inhibition in cancer therapy 6
- Molecular Biology top 2%
- Angiogenesis and VEGF in Cancer 12
- Cancer therapeutics and mechanisms 6
- Histone Deacetylase Inhibitors Research 6
- Cancer Research top 5%
- Genetics top 2%
- Connective tissue disorders research 15
- Immunology and Allergy top 5%
-
- Quinazolinone synthesis and applications 9
-
- Bone and Dental Protein Studies 6
- Co-authors
- Bryan SykesB P WordsworthStephen R. WedgeJane KendrewLaurent HennequinJon CurwenElaine S. E. StokesAndrew P. Thomas
- Journals
- The Lancet (2 papers)Nucleic Acids Research (3 papers)JNCI Journal of the National Cancer Institute (1 paper)
- Partner nations
- United KingdomFranceUnited States
In The Last Decade
Donald Ogilvie
82 papers receiving 4.4k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 1.3k
- Molecular Biology 2.6k
- Cancer Research 501
- Genetics 859
- Immunology and Allergy 143
Countries citing papers authored by Donald Ogilvie
This map shows the geographic impact of Donald Ogilvie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald Ogilvie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald Ogilvie more than expected).
Fields of papers citing papers by Donald Ogilvie
This network shows the impact of papers produced by Donald Ogilvie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald Ogilvie. The network helps show where Donald Ogilvie may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Donald Ogilvie, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 13 | |
| 2 | 2017 | 10 | |
| 3 | 2016 | 10 | |
| 4 | 2012 | 15 | |
| 5 | The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cellsbreakdown → | 2012 | 432 |
| 6 | 2011 | 72 | |
| 7 | 2008 | 10 | |
| 8 | Examining inhibition of VEGFR and EGFR signaling in MMTV-neu transgenic mice with well-established tumors: an immunohistochemical and oncogenomic analysis of AZD2171, vandetanib and gefitinib treatment | 2007 | 1 |
| 9 | 2007 | 70 | |
| 10 | 2007 | 23 | |
| 11 | 2006 | 29 | |
| 12 | 2005 | 31 | |
| 13 | The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo | 2004 | 7 |
| 14 | 2003 | 3 | |
| 15 | 2000 | 6 | |
| 16 | 1998 | 97 | |
| 17 | A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clonesbreakdown → | 1990 | 569 |
| 18 | Segregation of all four major fibrillar collagen genes in the Marfan syndrome. | 1987 | 34 |
| 19 | 1986 | 28 | |
| 20 | 1976 | 19 |
About Donald Ogilvie
Donald Ogilvie is a scholar working on Oncology, Immunology and Allergy and Anatomy, having authored 82 papers that have together received 4.5k indexed citations. Recurring topics across this work include Connective tissue disorders research (15 papers), Angiogenesis and VEGF in Cancer (12 papers), HER2/EGFR in Cancer Research (12 papers), Quinazolinone synthesis and applications (9 papers), Cancer therapeutics and mechanisms (6 papers), Histone Deacetylase Inhibitors Research (6 papers), PARP inhibition in cancer therapy (6 papers) and Bone and Dental Protein Studies (6 papers). The work is most often cited by research in Oncology (1.3k citations), Molecular Biology (2.6k citations) and Cancer Research (501 citations). Donald Ogilvie has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Bryan Sykes, B P Wordsworth, Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Jon Curwen, Elaine S. E. Stokes, Andrew P. Thomas, Rakesh Anand and John Anderson. Their work appears in journals such as The Lancet, Nucleic Acids Research and JNCI Journal of the National Cancer Institute.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.